All In Biotech

Free tool

FAERS Monitor: Janumet Xr

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 202270 or its brand name (Janumet Xr, Metformin Hydrochloride, Sitagliptin Phosphate). Reports on generic versions are filed under their own applications.

Reports

21,623

Serious

14,062

65% of reports

Hospitalization

7,059

Death reported

2,125

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • blood glucose increased1,511
  • diarrhoea1,398
  • nausea1,110
  • drug ineffective1,006
  • fatigue902
  • acute kidney injury838
  • vomiting781
  • weight decreased718
  • dizziness639
  • pancreatitis626
  • dyspnoea623
  • no adverse event623
  • inappropriate schedule of drug administration617
  • product dose omission issue614
  • death606

Reports by year received

View as table
YearReports
200739
2008131
2009254
2010384
2011539
2012929
20131,368
20141,814
20152,375
20162,094
20171,659
20181,792
20191,645
20201,564
20211,323
20221,058
2023926
2024752
2025598
2026379

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,032,536 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
pancreatitisSignal62611.610.86,026
inappropriate schedule of drug administrationSignal6178.57.94,055
blood glucose increasedSignal1,5117.97.59,042
acute kidney injurySignal8385.45.02,965
no adverse eventSignal6233.43.11,032
weight decreasedSignal7182.52.3655
diarrhoeaSignal1,3982.12.0838
product dose omission issueSignal6142.01.9325
vomiting7811.61.5187
nausea1,1101.41.3112
dizziness6391.21.232
fatigue9021.11.113
dyspnoea6231.11.03
drug ineffective1,0060.70.796
death6060.70.692

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.